NovoCure Ltd (NovoCure) is focused on the development and commercialization of novel delivery systems for the treatment of cancers of brain, thoracic and abdomen. Its proprietary Tumor Treating Fields (TTF) technology platform uses electric fields tuned to specific frequencies for disrupting the division of solid tumor cancer cells. The company markets TTF-based delivery systems: Optune Lua for the treatment of malignant pleural mesothelioma; and Optune for the treatment of glioblastoma. Both the products are indicated in combination with standard chemotherapies. Its product development and clinical programs strive to improve the survival of patients suffering from pancreatic cancer, brain metastases, ovarian cancer, liver cancer, gastric cancer, and non-small cell lung cancer, among others. It has subsidiaries in Europe, the Middle East, Asia, and North America. NovoCure is headquartered in Saint Helier, Jersey, the UK.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company NovoCure Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- NovoCure Ltd Company Overview
- NovoCure Ltd Company Snapshot
- NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
- NovoCure Ltd - Pipeline Analysis Overview
- Business Description
- NovoCure Ltd - Key Facts
- NovoCure Ltd - Major Products and Services
- NovoCure Ltd Pipeline Products by Development Stage
- NovoCure Ltd Ongoing Clinical Trials by Trial Status
- NovoCure Ltd Pipeline Products Overview
- Maxpoint Treatment Planning Software
- Maxpoint Treatment Planning Software Product Overview
- Next Gen Field Generator
- Next Gen Field Generator Product Overview
- NovoTTF-100M System
- NovoTTF-100M System Product Overview
- NovoTTF-100M System Clinical Trial
- NovoTTF-200A - Small Cell Lung Cancer
- NovoTTF-200A - Small Cell Lung Cancer Product Overview
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer Product Overview
- NovoTTF-200T - Pancreatic Cancer
- NovoTTF-200T - Pancreatic Cancer Product Overview
- NovoTTF-200T - Pancreatic Cancer Clinical Trial
- Optune - Brain Metastasis
- Optune - Brain Metastasis Product Overview
- Optune - Brain Metastasis Clinical Trial
- Optune - Breast Cancer
- Optune - Breast Cancer Product Overview
- Optune - Cervical Cancer
- Optune - Cervical Cancer Product Overview
- Optune - Colorectal Carcinoma
- Optune - Colorectal Carcinoma Product Overview
- Optune - Ependymoma
- Optune - Ependymoma Product Overview
- Optune - Gastric Adenocarcinoma
- Optune - Gastric Adenocarcinoma Product Overview
- Optune - Gastric Adenocarcinoma Clinical Trial
- Optune - Gliosarcoma
- Optune - Gliosarcoma Product Overview
- Optune - Liver Cancer
- Optune - Liver Cancer Product Overview
- Optune - Malignant Melanoma
- Optune - Malignant Melanoma Product Overview
- Optune - Medulloblastoma
- Optune - Medulloblastoma Product Overview
- Optune - Meningioma
- Optune - Meningioma Product Overview
- Optune - Mesothelioma
- Optune - Mesothelioma Product Overview
- Optune - Mesothelioma Clinical Trial
- Optune - Non-Small Cell Lung Cancer
- Optune - Non-Small Cell Lung Cancer Product Overview
- Optune - Non-Small Cell Lung Cancer Clinical Trial
- Optune - Ovarian Cancer
- Optune - Ovarian Cancer Product Overview
- Optune - Ovarian Cancer Clinical Trial
- Optune - Pancreatic Cancer
- Optune - Pancreatic Cancer Product Overview
- Optune - Pancreatic Cancer Clinical Trial
- Optune - Pediatric Glioma
- Optune - Pediatric Glioma Product Overview
- Optune - Pediatric Glioma Clinical Trial
- Optune - Renal Adenocarcinoma
- Optune - Renal Adenocarcinoma Product Overview
- Optune - Small Cell Lung Cancer
- Optune - Small Cell Lung Cancer Product Overview
- Optune - Torso Array
- Optune - Torso Array Product Overview
- Optune - Torso Array Clinical Trial
- Optune - Urinary Transitional Cell Carcinoma
- Optune - Urinary Transitional Cell Carcinoma Product Overview
- Optune Plus Bevacizumab - Recurrent Glioblastoma
- Optune Plus Bevacizumab - Recurrent Glioblastoma Product Overview
- Optune Plus Bevacizumab - Recurrent Glioblastoma Clinical Trial
- Optune With Marizomib And Temozolomide - Glioblastoma
- Optune With Marizomib And Temozolomide - Glioblastoma Product Overview
- Optune With Pembrolizumab And Temozolomide
- Optune With Pembrolizumab And Temozolomide Product Overview
- Optune With Pembrolizumab And Temozolomide Clinical Trial
- NovoCure Ltd - Key Competitors
- NovoCure Ltd - Key Employees
- NovoCure Ltd - Key Employee Biographies
- NovoCure Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- NovoCure Ltd, Recent Developments
- Feb 23, 2023: Allyson J. Ocean Joins Novocure Board of Directors
- Jan 09, 2023: Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
- Nov 17, 2022: Novocure announces 25 abstracts on tumor treating fields therapy at Society for Neuro-Oncology 2022 Annual Meeting
- Nov 15, 2022: Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
- Sep 21, 2022: Novocure announces Creation of U.S. CNS cancers franchise intended to renew focus on growth in glioblastoma business
- Apr 08, 2022: Novocure Announces 19 Presentations at American Association for Cancer Research (AACR) Annual Meeting 2022 Suggesting Broad Applicability of Tumor Treating Fields
- Feb 24, 2022: New data finds tumor treating fields initiates downstream anti-tumor response
- Feb 24, 2022: Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
- Jan 10, 2022: Novocure Announces Preliminary Full Year and Fourth Quarter 2021 Net Revenues and Provides Company Update
- Dec 06, 2021: Novocure announces 4th Annual AACR-Novocure grants for tumor treating fields research program
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
- NovoCure Ltd Pipeline Products by Equipment Type
- NovoCure Ltd Pipeline Products by Indication
- NovoCure Ltd Ongoing Clinical Trials by Trial Status
- NovoCure Ltd, Key Facts
- NovoCure Ltd, Major Products and Services
- NovoCure Ltd Number of Pipeline Products by Development Stage
- NovoCure Ltd Pipeline Products Summary by Development Stage
- NovoCure Ltd Ongoing Clinical Trials by Trial Status
- NovoCure Ltd Ongoing Clinical Trials Summary
- Maxpoint Treatment Planning Software - Product Status
- Maxpoint Treatment Planning Software - Product Description
- Next Gen Field Generator - Product Status
- Next Gen Field Generator - Product Description
- NovoTTF-100M System - Product Status
- NovoTTF-100M System - Product Description
- NovoTTF-100M System - Pivotal, Open-label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
- NovoTTF-100M System - Safety and Efficacy of SRS and Immune Checkpoint Inhibitors (ICI) Concurrent With NovoTTF-100M in Melanoma Brain Metastases
- NovoTTF-200A - Small Cell Lung Cancer - Product Status
- NovoTTF-200A - Small Cell Lung Cancer - Product Description
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - Product Status
- NovoTTF-200T - Advanced Non-Small Cell Lung Cancer - Product Description
- NovoTTF-200T - Pancreatic Cancer - Product Status
- NovoTTF-200T - Pancreatic Cancer - Product Description
- NovoTTF-200T - Pancreatic Cancer - A Phase II Study of Peri-Operative NovoTTF-200T in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
- Optune - Brain Metastasis - Product Status
- Optune - Brain Metastasis - Product Description
- Optune - Brain Metastasis - Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
- Optune - Brain Metastasis - Prophylactic Tumor Treating Fields in Management of Patients with Small Cell Lung Cancer
- Optune - Breast Cancer - Product Status
- Optune - Breast Cancer - Product Description
- Optune - Cervical Cancer - Product Status
- Optune - Cervical Cancer - Product Description
- Optune - Colorectal Carcinoma - Product Status
- Optune - Colorectal Carcinoma - Product Description
- Optune - Ependymoma - Product Status
- Optune - Ependymoma - Product Description
- Optune - Gastric Adenocarcinoma - Product Status
- Optune - Gastric Adenocarcinoma - Product Description
- Optune - Gastric Adenocarcinoma - A Phase II Pilot Study of Tumor Treating Fields Together with Chemotherapy as First-line Treatment of Gastric Cancer
- Optune - Gliosarcoma - Product Status
- Optune - Gliosarcoma - Product Description
- Optune - Liver Cancer - Product Status
- Optune - Liver Cancer - Product Description
- Optune - Malignant Melanoma - Product Status
- Optune - Malignant Melanoma - Product Description
- Optune - Medulloblastoma - Product Status
- Optune - Medulloblastoma - Product Description
- Optune - Meningioma - Product Status
- Optune - Meningioma - Product Description
- Optune - Mesothelioma - Product Status
- Optune - Mesothelioma - Product Description
- Optune - Mesothelioma - TTFields in General Routine Clinical Care in Patients With Pleural Mesot
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- MagForce AG
- Advanz Pharma Corp Ltd
- SonALASense Inc
- Flowonix Medical Inc
- MDxHealth SA
- Hologic Inc
- Monteris Medical Inc
